Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07214740 | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | PHASE3 | COMPLETED | 44 | — | — | Oct 24, 2025 | Dec 12, 2025 | Dec 17, 2025 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Pegcetacoplan, 15 mg/100 μL (single dose), intravitreal injection via prefilled syringe | EXPERIMENTAL | This is a 30-day, phase 3b, single-arm, open-label, multicenter study to evaluate the safety of IVT pegcetacoplan administered via PFS in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study consists of a screening/baseline visit at day 1, a follow-up call at day 7, and an end of study visit at day 30. |
| Name | Type | Description |
|---|---|---|
| APL-2, Pegcetacoplan | DRUG | Complement (C3) Inhibitor |
Inclusion Criteria: 1. Participants must be aged at least 60 years and have a diagnosis of GA secondary to AMD. 2. Participants must have adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images in the study eye as determined by the...